Evidence on different risk rates among anti-VEGF agents not significant at present

COPENHAGEN, Denmark — At present, there is not sufficient data to prove that the three anti-VEGF agents currently used to treat wet age-related macular degeneration have different risks of systemic side effects, and more evidence needs to be provided by clinical trials, according to a speaker. Although a slightly higher proportion of systemic adverse events was found with Avastin (bevacizumab, Genentech) in the CATT and IVAN trials, significance is not strong enough to draw conclusions, Tien Y. Wong, MD, said at the meeting of the European Society of Ophthalmology.

Full Story →